Clover Health delivered results ahead of Wall Street expectations in the third quarter, driven by robust membership growth and improved operational performance. Management credited its clinically focused AI technology, Clover Assistant, for enhancing care quality and enabling more efficient cost management across its physician network. CEO Andrew Toy highlighted that increased Clover Assistant engagement and a disciplined growth strategy contributed to higher gross profit and operating margin expansion. The company also benefited from favorable inpatient utilization trends and better-than-expected performance in its Part D prescription drug line.
Is now the time to buy CLOV? Find out in our full research report (it’s free for active Edge members).
Clover Health (CLOV) Q3 2026 highlights:
- Revenue $759.3 million vs S&P analysts’ estimates of $740.3 million (52.9% year-on-year growth, 2.6% beat)
- Adjusted EPS $0.03 vs S&P analysts’ estimates of $0.01 ($0.02 beat)
- Adjusted EBITDA $16.05 million vs analyst estimates of $10.11 million (2.1% margin, 58.7% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $2.99 billion at the midpoint from $2.96 billion
- EBITDA guidance $80 million at the midpoint for the full year, in line with analyst expectations
- Operating margin 0.8%, up from -4.9% in the same quarter last year
- Customers 158,907, up from 157,309 in the previous quarter
- Market capitalization $2.39 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from Clover Health’s Q3 earnings call
- John Pinney (Canaccord Genuity) asked how accelerating Clover Assistant coverage compares to the company's historical two-thirds engagement metric. CFO Clay Thornton explained current coverage is ahead of last year’s pace and is tracking well toward the two-thirds goal.
- Jonathan Yong (UBS) inquired whether higher Clover Assistant coverage could lead to greater-than-normal improvements in gross profit per member. Thornton said cohort maturation economics are closely tied to coverage levels, so higher coverage should enhance profitability.
- Matthew Shea (Needham) questioned the impact of competitor exits and new entrants in New Jersey on AEP switching dynamics. Thornton confirmed that plan exits and market changes were anticipated and factored into plan design, with early results showing strong growth and competitive positioning.
- Graham Harrison (Deutsche Bank) asked about the balance between earnings retention and reinvestment as cohort maturation and Star improvements drive incremental benefits. Thornton noted planning for 2027 is still underway and did not provide specific figures, but expects the model will absorb growth while delivering maturation-driven improvements.
- Dean Rosales (Leerink Partners) sought clarification on contingency planning for potential regulatory changes due to a pending government appeal. CEO Andrew Toy said the company is monitoring developments and feels confident in its current position, but will address changes if necessary.
Catalysts in upcoming quarters
In upcoming quarters, the StockStory team will be watching (1) the pace and breadth of Clover Assistant adoption across both new and existing members, (2) the impact of cohort maturation on gross profit and operating margin expansion, and (3) the competitive response to plan exits and new entrants in core markets like New Jersey and Georgia. Progress in automating administrative processes and any regulatory developments will also be key areas to monitor.
Clover Health currently trades at $4.45, down from $4.67 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
The best stocks for high-quality investors
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
